Key result
Visfatin/NAMPT is an adipokine that correlates with systemic inflammation and may serve as a biomarker for cardiovascular disease and plaque instability in patients with metabolic syndrome.
Visfatin/NAMPT is an emerging biomarker of inflammation in metabolic syndrome that correlates with cardiovascular disease and plaque instability, though further studies are needed to clarify its exact pathophysiological role.
Hypothesis-generating for visfatin as an inflammatory biomarker; should not yet change clinical practice or risk stratification.
As it had been already stated by latest research, inflammation is a condition which sits at the very base of atherogenesis, which is the major consequence of the metabolic syndrome. It was stated that adipose tissue impacts all organs by the synthesis of adipokines. Visfatin/NAMPT is a biomarker that was recently discovered in mice (2005). In the beginning it was believed to have insulin-like properties, but afterwards research has found important links between Visfatin and inflammation, endothelial dysfunction and atherosclerosis in coronary artery disease. It was also linked to plaque instability in acute coronary syndromes. More studies are needed though, to clearly state whether Visfatin/NAMPT has a positive or negative role because, up until now, the only sure fact is that its serum levels correlate with the presence of an inflammatory state.
No takes yet. Share an insight, caveat, or question.
Hognogi et al. (2015) conducted a review in Metabolic syndrome and cardiovascular disease. Visfatin/NAMPT was evaluated. Visfatin/NAMPT is an adipokine that correlates with systemic inflammation and may serve as a biomarker for cardiovascular disease and plaque instability in patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: